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Abstract
Background: Currently, no system for appropriate intra-hospital collaboration regarding hepatitis virus positive
individuals exists, even in medical institutions with hepatologists among their staff. The main objective of this
study was to explore a simple alert system to promote the referral of patients with hepatitis B surface antigen
(HBsAg)- or anti-hepatitis C virus (HCV) antibodies positivity to hepatologists through electronic medical records.
Methods: Since April 2014 at Osaka City Juso Hospital, “sticky notes” have been put on the electronic medical
records of patients newly diagnosed with HBsAg- or anti-HCV- antibodies positivity to recommend intra-hospital
referral of those patients to specialists. In this study, we investigated the number of referrals to hepatologists
before vs. after the introduction of this system (that is, in fiscal years 2013 [Period 1] and 2014 [Period 2],
respectively), and the subsequent clinical courses of the patients.
Results: The proportions of patients with HBsAg and anti-HCV antibody positivity did not show statistically
significant differences between Period 1 and Period 2 (1.6 % [43/2,757] vs. 1.3 % [39/2,891], p = 0.58; and
5.8 % [156/2,674] vs. 5.3 % [147/2,790], p = 0.39, respectively). However, the referral proportions for patients
with HBsAg- and anti-HCV antibody positivity were significantly higher in Period 2 (73 % [11/15] and 65 %
[41/63], respectively) than in Period 1 (28 % [5/18] and 17 % [9/54]) (p = 0.009 and p < 0.001, respectively).
Among patients who were referred to hepatologists, 2 HBsAg-positive and 4 anti-HCV antibody positive
patients initiated antiviral treatment.
Conclusion: Our simple electronic medical record based alert system effectively promoted intra-hospital
referral of hepatitis virus-positive patients, who have been detected by screening tests, to hepatologists.
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Background
Chronic infection with hepatitis B virus (HBV) and
hepatitis C virus (HCV) is the major cause of end-stage
liver diseases, including cirrhosis and hepatocellular
carcinoma [1, 2]. However, disease progression and can-
cer development can be inhibited by antiviral treatment
[3–6], especially with the recent advances in these anti-
viral treatments. Thus, referral of hepatitis virus- posi-
tive individuals to a hepatologist at least once in their
lifetime is recommended [7]. Unfortunately, in many
Western countries, even though patients are successfully
screened, many do not receive confirmatory testing for
HBV or HCV [8–11].
In Japan, although medical check-ups for HBV and
HCV infection are conducted nationwide, not all
those who are found to be positive for these viruses
seek specialist medical attention or receive proper
treatment from a hepatologist. Thus, the government
is collaborating with two in-country civil society
groups-the Japan Hepatitis Council and the Viral
Hepatitis Research Foundation of Japan-to develop
and implement its viral hepatitis prevention and
control program [12]. In hospitals, testing for HBV
and HCV is performed as part of daily practice, as a
preoperative or pretransfusion screening test. How-
ever, the efficiency of intra-hospital collaboration
with hepatologists in relation to the follow-up treat-
ment of HBV- or HCV- positive individuals detected
by screening tests remains unclear. Recently, Furu-
kawa et al. reported on the current management
practices for patients with hepatitis B surface antigen-
(HBsAg-) and anti-HCV- antibody positivity in non-
hepatology departments at Saga University Hospital
[13]. The prevalence proportions of HBsAg- and anti-
HCV antibody positive individuals were 1.9 and
5.6 %, respectively. However, 79 % of HBV- and 82 %
of probable HCV- positive patients were not referred
to hepatologists. To address this issue, a system to
manage hepatitis virus- positive patients and to
ensure that they receive specialist care should be
established as soon as possible in medical institutions
that have hepatologists among their staff.
We developed a simple alert system to promote
the referral of HBsAg- or anti-HCV antibody positive
patients to hepatology specialists through their elec-
tronic medical records. In this exploratory study, we
investigated the changes in the number of referrals
to hepatologists and in the distribution of patients
referred after the introduction of the system, as well
as the subsequent clinical courses of the patients
following these referrals. Herein, we present our
results. Further improvements needed for intra-




This was a single-center study of both inpatients and
outpatients conducted in a secondary-care hospital. The
investigation consisted of two parts, a retrospective in-
vestigation of the pre-intervention period (from April 1,
2013, to March 31, 2014; defined as “Period 1”) and a
prospective investigation during the post-intervention
period (from April 1, 2014, to March 31, 2015; defined
as “Period 2”).
Development of an alert system for promoting referrals
of HBsAg- or anti-HCV antibody positive patients to a
specialist department
Osaka City Juso Hospital is a community hospital with
263 beds (5 wards). Outpatient services are provided by
15 clinical departments, and approximately 500 patients
visit the hospital daily. The personal identification num-
bers of newly diagnosed patients with HBsAg- or anti-
HCV antibody positivity were sent from the hospital’s
central laboratory to the principal investigator through
the hospital intranet every Monday afternoon during
Period 2. After receiving these numbers, the principal in-
vestigator entered the following comment, referred to as
a “sticky note,” in the electronic medical records of any
patient who had not been referred to a hepatologist :
“This patient was found to be positive for HBsAg (or
anti-HCV antibody) in this test. Please consider referring
the patient to a hepatologist.” This was done every
Thursday evening. Once “sticky noted,” every user of the
medical record was forced to see this “sticky note”. The
cut-off for the presence or absence of referral for the
purposes of the study was set as 1 month after the med-
ical records were “sticky noted.”
We compared the number of patients screened for
either HBV or HCV in Period 2 with that in Period 1.
The distribution across the referring departments of
patients who were referred to a hepatologist from non-
hepatology departments and the patients’ clinical courses
after the referral was examined. The primary outcome of
this study was the referral proportion to a hepatologist.
The referral proportion was calculated as follows: referral
proportion = number of patients referred to a hepatolo-
gist/ number of patients who attended a non-hepatologist
appointment to receive a positive test result of HBsAg or
anti-HCV antibody × 100.
The study protocol and informed consent proced-
ure were approved by the Institutional Review Board
at Osaka City Juso Hospital, and the study was
conducted in accordance to the concepts of the
Declaration of Helsinki. The Institutional Review Board
gave permission to collect data without informed
consent.
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Hepatitis virus testing
HBsAg was measured using the Architect HBsAg QT
assay (Abbott Japan, Tokyo), and anti-HCV antibodies
were measured using the Architect HCV assay (Abbott
Japan, Tokyo). HBV-DNA was measured using COBAS
TaqMan HBV Test v. 2.0 (Roche Diagnostics K.K., Tokyo,
Japan), and HCV-RNA was measured using the COBAS
TaqMan HCV Test v. 2.0 (Roche Diagnostics K.K.).
Statistical analysis
Statistical analysis was conducted using JMP 11.0 soft-
ware (SAS Institute, Inc., Cary, NC). Fisher’s exact prob-
ability test or the chi-square test was used for
categorical factors. As no participant appeared in the
study periods, these tests were considered valid and
appropriate. Differences with p values <0.05 were con-
sidered statistically significant.
Results
Status of HBsAg and anti-HCV antibody testing
In Period 1, of the 2,757 patients in whom HBsAg was
measured, 43 (1.6 %) were found to be positive, and of
the 2,674 patients who underwent anti-HCV antibody
measurements, 156 (5.8 %) were found to be positive
(Fig. 1a). In Period 2, of the 2,891 patients in whom
HBsAg was measured, 39 (1.3 %) were found to be posi-
tive, and of the 2,790 patients who underwent anti-HCV
antibody measurements, 147 (5.3 %) were found to be
positive (Fig. 1b). The proportions of patients with
HBsAg and anti-HCV antibody positivity did not show
statistically significant differences between Period 1 and
Period 2 (p = 0.58 and p = 0.39, respectively). We put
“sticky notes” on the records for the 23 HBsAg- positive
and 81 anti-HCV antibody positive patients who were
not immediately referred to a hepatologist (Fig. 1b).
Fig. 1 Flow chart of subjects who underwent screening tests for HBsAg or anti-HCV antibody. a in Period 1. b in Period 2. HBsAg, hepatitis B
surface antigen; HCV, hepatitis C virus
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Referral proportions of “sticky noted” patients to
hepatologists
Figure 2a, b show the flow charts of the study subjects
who were found to be positive for HBsAg or anti-HCV
antibody in non-hepatology departments and recom-
mended to consult hepatologists (“sticky noted”) in
Periods 1 and 2, respectively. Patients who did not at-
tend the non-hepatologist appointment to receive the
positive test results (ie those who were still unaware of
their infection status) were excluded from the analysis of
the referral proportions. The referral proportions for
both HBsAg and anti-HCV antibody positive patients
were significantly higher in Period 2 (73 % [11/15] and
65 % [41/63], respectively) than in Period 1 (28 % [5/18]
and 17 % [9/54]) (p = 0.009 and p < 0.001, respectively).
Distributions across referring non-hepatology depart-
ments of patients referred to a hepatologist during
Period 2
Across the clinical departments of the hospital, the num-
bers of patients who were “sticky noted” in Period 2
were as follows: Orthopedics (n = 22), Respiratory Medi-
cine (n = 20), Gastroenterology (n = 18), Urology (n =
11), Surgery (n = 11), Ophthalmology (n = 9), Obstetrics
and Gynecology (n = 7), Diabetic Medicine (n = 4), and
Pediatrics (n = 2). Of these, the numbers of patients who
were actually referred to hepatologists were as follows:
Gastroenterology (n = 13 [72 %]), Respiratory Medicine
(n = 11 [55 %]), Orthopedics (n = 9 [41 %]), Obstetrics
and Gynecology (n = 5 [71 %]), Urology (n = 4 [36 %]),
Surgery (n = 3 [27 %]), Ophthalmology (n = 3 [33 %]),
Diabetic Medicine (n = 2 [50 %]), and Pediatrics (n = 2
[100 %]) (Additional file 1: Figure S1).
Outcomes of patients referred to hepatologists
As shown in Fig. 2a, b, of the 23 HBsAg positive
patients who were “sticky noted,” 11 ultimately consulted
a hepatologist; of these, two started nucleoside analogue
treatment, while nine were found to be inactive HBV-
positive patients who required only periodic follow- up.
Of the 81 anti-HCV antibody- positive patients who were
“sticky noted,” 41 ultimately consulted a hepatologist; of
these, four started interferon-based or first-generation
interferon-free treatment, ten were listed as being consid-
ered for next-generation antiviral treatment, and 27 were
negative for HCV-RNA. The clinical backgrounds of the
six patients who received antiviral treatment are shown in
Additional file 2: Table S1.
Discussion
We developed a simple alert system to refer HBsAg- or
anti-HCV antibody- positive patients to hepatologists
Fig. 2 HBsAg or anti-HCV antibody positive subjects in non-hepatology departments referred to hepatologists (“sticky noted”). a in Period 1. b in
Period 2. HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus
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through electronic medical records. The main finding of
this study was that our system could increase the num-
ber of referrals of hepatitis virus-positive patients
detected by screening tests to hepatologists. Similarly,
Shimomura et al. recently reported that the implementa-
tion of a fully automated reporting system relying on
electronic medical records at Okayama University
Hospital also increased the number of referrals of
HBsAg- or anti-HCV antibody- positive patients to the
Hepatology department [14], indicating that such alert
system may have the potential to promote intra-hospital
referrals in other areas as well. For example, HbA1C is
widely used as a screening tool for diabetes mellitus
[15], and thus may help promote intra-hospital referrals
of high-risk diabetic patients to specialists.
Electronic medical records have the potential to pro-
vide substantial benefits to physicians, clinical practices,
and health care organizations [16], with the system
optimization process being defined as the continuing
effort to help users maximize their proficiency in the use
of the system [17]. Our alert system has certain import-
ant advantages. First, this system is easy to operate.
Although it is a manual system, it requires little effort to
implement. We created approximately 100 “sticky notes”
on the patients’ electronic medical records over the
course of 1 year; this is equivalent to 1 “sticky note”
every 3 days, and it takes only a minute or two to place
such a “sticky note”. This level of additional workload
seems to be acceptable even for busy medical staff. Next,
this system is free to use, and it is easy to optimize the
existing electronic medical record- based systems. More-
over, in relatively small community hospitals like ours,
where care decisions are generally made in only a short
time, it is easy to familiarize the staff with this system.
In Japan, the numbers of anti-HCV antibody- and
HBsAg- positive individuals are estimated to be 1.5–2
million and 1.3–1.5 million, respectively. However,
Tanaka et al. estimated that approximately 800,000 anti-
HCV antibody- positive and 900,000 HBsAg-positive
individuals are not aware that they are infected [18].
Moreover, the national Ministry of Health, Labour, and
Welfare Ministerial Notification No. 160 (released on
May 16, 2011) requested that medical institutions prop-
erly explain the results of hepatitis virus testing to the
individuals tested. Although antiviral treatment has
advanced substantially, if infected patients screened on
various occasions do not consult a hepatologist and
receive proper treatment, they will not benefit from the
recent advances made in antiviral treatment. Additionally,
even when the viruses are eliminated, cancer may some-
times develop, especially in older patients and in those
with advanced fibrosis. Thus, unless proper follow-up is
continued over the lifetime of the patients, reductions in
liver-related deaths cannot ultimately be achieved.
Even with “sticky notes”, the referral proportion was
still comparably low in some departments in our
hospital (<50 % referral proportions in the Orthopedics,
Urology, Surgery, and Ophthalmology Departments).
The reason for this low proportion is unclear, but it is
probable that the referral proportion varies with the
varying awareness of the physicians regarding appropri-
ate responses for patients with hepatitis virus infection.
It is also necessary for hepatologists to make efforts to
inform physicians in non-hepatology departments about
the recent advances in antiviral treatments at any oppor-
tunity, for example at conferences.
Some limitations of this study should be mentioned.
First, the referral proportion did not directly reflect the
number of patients who subsequently received care for
HBV or HCV infection. One reason is that some patients
referred to hepatologists have already received care for
HBV or HCV in other hospitals. Second, this was a single-
centre study conducted in a secondary care hospital. A
manual “sticky note” system as utilized in this study may
be of little relevance or clinical assistance in tertiary care
hospitals or public health settings. Third, some con-
founders, such as staff education, awareness of clinical
trials, and availability of antiviral therapy for HBV and
HCV may have affected the referral proportions.
Conclusions
In conclusion, the simple, electronic medical record-
based alert system described herein was found to be ef-
fective for promoting intra-hospital referrals of hepatitis
virus positive patients detected by screening tests to
hepatologists. In addition, improved knowledge and
awareness of HBV and HCV infection among healthcare
service providers appear important in terms of enabling
intra-hospital collaborations and specialist referrals.
Additional files
Additional file 1: Distribution of patients in non-hepatology departments
who were referred to hepatologists in Period 2. (PPTX 51 kb)
Additional file 2: Detailed data about the patients (n = 6) who received
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